In 2007, the Food and Drug Administration approved MESOMARK, a blood test for detecting mesothelioma. MESOMARK measures the blood serum concentrations of a marker called soluble mesothelin-related protein (SMRP), which are high in people who have mesothelioma. The manufacturers of this product, Fujirebio Diagnostics, Inc., hope that MESOMARK will allow doctors to diagnose mesothelioma at its early stages, when it may be more susceptible to treatment. MESOMARK can be used along with other procedures, such as x-rays and patient history, to diagnose and monitor cases of mesothelioma.
If you or a loved one has been diagnosed with mesothelioma, fill out our free case evaluation form to speak with a mesothelioma lawyer today.
By measuring the amount of SMRP present in the bloodstream, the MESOMARK blood test helps physicians routinely monitor individuals who are at risk for developing mesothelioma due to asbestos exposure. In order to perform the MESOMARK test, a blood sample is taken from the patient and then sent to a laboratory for testing. The laboratory determines the amount of SMRP present in the blood by using monoclonal antibodies known to specifically bind to SMRP. Physicians can use the MESOMARK test results to assist them in making decisions about the management of patients with mesothelioma. Increasing results may indicate that the disease is progressing, while decreasing or constant results may be indicative of response to therapy, or stable disease.
1-877-MORGAN-LAW
Guided Case Review